Recent studies indicate the presence of pre-existing BCR-ABL mutations in a higher percentage of CML patients when CD34+ stem/progenitor cells are investigated using sensitive techniques, and these mutations are associated with imatinib resistance and disease progression. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.